tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Robert Leboyer, 8 are a BUY (100%).
Analyst Robert Leboyer, currently employed at NOBLE CAPITAL, carries an average stock price target met ratio of 50% that have a potential upside of 49.67% achieved within 306 days.
Robert Leboyer’s has documented 12 price targets and ratings displayed on 3 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on TNXP, Tonix Pharmaceuticals Holding Corp at 20-Mar-2025.
Analyst best performing recommendations are on AXLA (AXCELLA HEALTH).
The best stock recommendation documented was for AXLA (AXCELLA HEALTH) at 10/13/2021. The price target of $6 was fulfilled within 706 days with a profit of $3.13 (109.06%) receiving and performance score of 1.54.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
2 years 1 months 18 days ago
(16-Feb-2023)
0/1 (0%)
$242.25 (224.83%)
Hold
$6
$5.15 (605.88%)
2 years 3 months 19 days ago
(15-Dec-2022)
1/1 (100%)
$-4.98 (-45.36%)
1
Buy
$5
$4.11 (461.80%)
2 years 5 months 1 days ago
(02-Nov-2022)
0/1 (0%)
$3.97 (385.44%)
Buy
$7
$-0.86 (-10.94%)
$12
2 years 5 months 1 days ago
(02-Nov-2022)
2/2 (100%)
$-25.13 (-72.62%)
132
Buy
2 years 8 months ago
(03-Aug-2022)
0/1 (0%)
$155.75 (42.18%)
Which stock is Robert Leboyer is most bullish on?
What Year was the first public recommendation made by Robert Leboyer?
